Neuroendocrine and Aggressive-Variant Prostate Cancer.
aggressive variant prostate cancer
anaplastic prostate cancer
castration resistant prostate cancer
neuroendocrine prostate cancer
small-cell prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Dec 2020
16 Dec 2020
Historique:
received:
20
10
2020
revised:
12
12
2020
accepted:
14
12
2020
entrez:
19
12
2020
pubmed:
20
12
2020
medline:
20
12
2020
Statut:
epublish
Résumé
In prostate cancer, neuroendocrine (NE) differentiation may rarely present de novo or more frequently arises following hormonal therapy in patients with castration-resistant prostate cancer (CRPC). Its distinct phenotype is characterized by an aggressive clinical course, lack of responsiveness to hormonal therapies and poor prognosis. Importantly, a subset of CRPC patients exhibits an aggressive-variant disease with very similar clinical and molecular characteristics to small-cell prostate cancer (SCPC) even though tumors do not have NE differentiation. This aggressive-variant prostate cancer (AVPC) also shares the sensitivity of SCPC to platinum-based chemotherapy albeit with short-lived clinical benefit. As optimal treatment strategies for AVPC remain elusive, currently ongoing research efforts aim to enhance our understanding of the biology of this disease entity and improve treatment outcomes for our patients. This review is an overview of our current knowledge on prostate cancer with NE differentiation and AVPC, with a focus on their clinical characteristics and management, including available as well as experimental therapeutic strategies.
Identifiants
pubmed: 33339136
pii: cancers12123792
doi: 10.3390/cancers12123792
pmc: PMC7765615
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Urol Int. 2019;102(4):373-384
pubmed: 30517936
Clin Cancer Res. 2013 Jul 1;19(13):3621-30
pubmed: 23649003
Urol Int. 2019;103(4):383-390
pubmed: 30965328
Am J Surg Pathol. 2014 Jun;38(6):756-67
pubmed: 24705311
Cancer. 2007 Oct 15;110(8):1729-37
pubmed: 17786954
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
Lancet Oncol. 2015 Feb;16(2):152-60
pubmed: 25601341
Anticancer Res. 2015 Jul;35(7):4145-50
pubmed: 26124369
Am J Surg Pathol. 2006 Aug;30(8):980-5
pubmed: 16861969
Eur Urol. 2019 Mar;75(3):378-382
pubmed: 30337059
Int J Biol Markers. 2018 Jan;33(1):10-21
pubmed: 28885659
Cancer. 1991 Jul 15;68(2):227-32
pubmed: 1712661
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
Hum Pathol. 2013 Oct;44(10):2227-33
pubmed: 23850495
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
Mod Pathol. 2018 Jan;31(S1):S122-132
pubmed: 29297494
Science. 2017 Jan 6;355(6320):78-83
pubmed: 28059767
Arch Pathol Lab Med. 2002 May;126(5):554-61
pubmed: 11958660
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
Can J Urol. 2019 Oct;26(5 Suppl 2):34-37
pubmed: 31629426
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Lancet Oncol. 2019 Oct;20(10):1432-1443
pubmed: 31515154
Ann Oncol. 2009 Apr;20(4):703-8
pubmed: 19179557
Anticancer Res. 2017 Sep;37(9):5117-5124
pubmed: 28870943
Cancer Cell. 2016 Oct 10;30(4):563-577
pubmed: 27728805
Endocr Relat Cancer. 1999 Dec;6(4):503-19
pubmed: 10730904
Am J Surg Pathol. 2006 Jun;30(6):684-93
pubmed: 16723845
Clin Cancer Res. 2019 Jan 1;25(1):43-51
pubmed: 30232224
Asian J Androl. 2018 Nov-Dec;20(6):561-566
pubmed: 30084431
Clin Cancer Res. 2016 Mar 15;22(6):1510-9
pubmed: 26671992
Am J Clin Oncol. 1989 Apr;12(2):114-7
pubmed: 2539716
J Urol. 2007 Sep;178(3 Pt 1):844-8; discussion 848
pubmed: 17631339
J Biol Chem. 2019 Jun 21;294(25):9911-9923
pubmed: 31085587
Int J Surg Pathol. 2010 Dec;18(6):550-3
pubmed: 20798067
Cancer. 2000 Jun 1;88(11):2590-7
pubmed: 10861438
Prostate. 1997 Jan 1;30(1):1-6
pubmed: 9018329
Biomark Res. 2018 Mar 9;6:10
pubmed: 29556394
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
Clin Cancer Res. 2014 Jun 1;20(11):2846-50
pubmed: 24727321
Ann Oncol. 2019 Nov 1;30(11):1813-1820
pubmed: 31560066
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
BJU Int. 2017 Aug;120(2):226-232
pubmed: 28107595
N Engl J Med. 2004 Oct 7;351(15):1513-20
pubmed: 15470214
J Clin Oncol. 2014 Oct 20;32(30):3383-90
pubmed: 25225419
Cancer J Sci Am. 1999 Jul-Aug;5(4):237-41
pubmed: 10439170
Cancer Manag Res. 2019 Apr 05;11:2747-2758
pubmed: 31114331
Hum Pathol. 2003 Jul;34(7):646-53
pubmed: 12874759
Eur J Cancer. 1993;29A(15):2094-6
pubmed: 7507687
Science. 2017 Jan 6;355(6320):84-88
pubmed: 28059768
Eur Urol. 2005 Aug;48(2):224-9; discussion 229-30
pubmed: 16005374
Am J Surg Pathol. 2008 Jan;32(1):65-71
pubmed: 18162772
Cancer Discov. 2011 Nov;1(6):487-95
pubmed: 22389870
Cancer. 1987 May 15;59(10):1803-9
pubmed: 3030528
Cancer. 1985 Feb 1;55(3):608-14
pubmed: 2578089
Pathol Res Pract. 1987 Jun;182(3):298-307
pubmed: 2442732
J Clin Oncol. 2019 Feb 1;37(4):286-295
pubmed: 30376427
Cancer Res. 2004 Dec 15;64(24):9209-16
pubmed: 15604294
Mod Pathol. 2011 Jun;24(6):820-8
pubmed: 21336263
Ann Oncol. 2001;12 Suppl 2:S141-4
pubmed: 11762342
Oncotarget. 2016 Aug 16;7(33):52810-52817
pubmed: 27429197
Am J Surg Pathol. 2006 Jun;30(6):705-12
pubmed: 16723847
Clin Cancer Res. 2017 Nov 15;23(22):6863-6874
pubmed: 28790115
Mol Ther. 2018 Jul 5;26(7):1855-1866
pubmed: 29807781
Sci Rep. 2018 Oct 18;8(1):15442
pubmed: 30337589
Neoplasia. 2013 Jan;15(1):1-10
pubmed: 23358695
Oncol Res Treat. 2018;41(10):627-633
pubmed: 30286478
Eur Urol. 2003 Aug;44(2):215-21
pubmed: 12875941
Urology. 2005 Jan;65(1):174
pubmed: 15667891
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
Eur J Cancer. 1994;30A(8):1058-60
pubmed: 7654428
JAMA Oncol. 2019 Apr 1;5(4):471-478
pubmed: 30589920
Arch Pathol Lab Med. 2020 Jan;144(1):18-23
pubmed: 31403335
J Natl Compr Canc Netw. 2014 May;12(5):719-26
pubmed: 24812138
Eur Urol. 2004 May;45(5):586-92; discussion 592
pubmed: 15082200
Sci Transl Med. 2019 Mar 20;11(484):
pubmed: 30894499
Lancet Oncol. 2020 Jan;21(1):162-174
pubmed: 31806540
Br J Cancer. 1999 Dec;81(8):1351-5
pubmed: 10604732
BJU Int. 2012 Mar;109(6):824-30
pubmed: 21883857
J Clin Oncol. 2002 Jul 15;20(14):3072-80
pubmed: 12118020
J Transl Med. 2020 Jan 14;18(1):23
pubmed: 31937346
Ann Oncol. 2011 Nov;22(11):2476-2481
pubmed: 21436186
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
Cancer. 2001 Sep 1;92(5):1101-7
pubmed: 11571721
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
N Engl J Med. 2019 Mar 28;380(13):1235-1246
pubmed: 30763142
Am J Surg Pathol. 1984 Jul;8(7):545-50
pubmed: 6204547
Arch Pathol Lab Med. 2006 Nov;130(11):1693-706
pubmed: 17076534
J Urol. 1992 Mar;147(3 Pt 2):935-7
pubmed: 1311396
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Urology. 1992 May;39(5):411-6
pubmed: 1315995
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Int J Urol. 2018 Apr;25(4):345-351
pubmed: 29396873
Ann Oncol. 2015 Sep;26 Suppl 5:v69-77
pubmed: 26205393
Clin Cancer Res. 2016 Mar 15;22(6):1520-30
pubmed: 26546618